The Mammalian Target of Rapamycin Regulates Cholesterol Biosynthetic Gene Expression and Exhibits a Rapamycin-resistant Transcriptional Profile

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2011 Aug 31

PMID 21876130

Citations 55

Authors

Beatrice T Wang

Gregory S Ducker

Andrea J Barczak

Rebecca Barbeau

David J Erle

Kevan M Shokat

Affiliations

Soon will be listed here.

Abstract

The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation in response to growth factor and nutrient signaling. Consequently, this kinase is implicated in metabolic diseases including cancer and diabetes, so there is great interest in understanding the complete spectrum of mTOR-regulated networks. mTOR exists in two functionally distinct complexes, mTORC1 and mTORC2, and whereas the natural product rapamycin inhibits only a subset of mTORC1 functions, recently developed ATP-competitive mTOR inhibitors have revealed new roles for both complexes. A number of studies have highlighted mTORC1 as a regulator of lipid homeostasis. We show that the ATP-competitive inhibitor PP242, but not rapamycin, significantly down-regulates cholesterol biosynthesis genes in a 4E-BP1-dependent manner in NIH 3T3 cells, whereas S6 kinase 1 is the dominant regulator in hepatocellular carcinoma cells. To identify other rapamycin-resistant transcriptional outputs of mTOR, we compared the expression profiles of NIH 3T3 cells treated with rapamycin versus PP242. PP242 caused 1,666 genes to be differentially expressed whereas rapamycin affected only 88 genes. Our analysis provides a genomewide view of the transcriptional outputs of mTOR signaling that are insensitive to rapamycin.

Citing Articles

Autophagy and the peroxisome proliferator-activated receptor signaling pathway: A molecular ballet in lipid metabolism and homeostasis.

Kiani P, Khodadadi E, Nikdasti A, Yarahmadi S, Gheibi M, Yousefi Z Mol Cell Biochem. 2025; .

PMID: 39891864 DOI: 10.1007/s11010-025-05207-0.

Targeting Neutrophil Extracellular Traps in Gouty Arthritis: Insights into Pathogenesis and Therapeutic Potential.

Li C, Wu C, Li F, Xu W, Zhang X, Huang Y J Inflamm Res. 2024; 17:1735-1763.

PMID: 38523684 PMC: 10960513. DOI: 10.2147/JIR.S460333.

Restrained Mitf-associated autophagy by Mulberroside A ameliorates osteoclastogenesis and counteracts OVX-Induced osteoporosis in mice.

Xue H, Feng Z, Yuan P, Qiao L, Lou Q, Zhao X Cell Death Discov. 2024; 10(1):80.

PMID: 38360705 PMC: 10869803. DOI: 10.1038/s41420-024-01847-1.

Multiomics analysis identifies novel facilitators of human dopaminergic neuron differentiation.

Gomez Ramos B, Ohnmacht J, de Lange N, Valceschini E, Ginolhac A, Catillon M EMBO Rep. 2024; 25(1):254-285.

PMID: 38177910 PMC: 10897179. DOI: 10.1038/s44319-023-00024-2.

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.

Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X Cell Stem Cell. 2023; 31(1):71-88.e8.

PMID: 38151022 PMC: 11022279. DOI: 10.1016/j.stem.2023.11.011.

References

Porstmann T, Griffiths B, Chung Y, Delpuech O, Griffiths J, Downward J . PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene. 2005; 24(43):6465-81. DOI: 10.1038/sj.onc.1208802. View

Nakamura Y, Sakakibara J, Izumi T, Shibata A, Ono T . Transcriptional regulation of squalene epoxidase by sterols and inhibitors in HeLa cells. J Biol Chem. 1996; 271(14):8053-6. DOI: 10.1074/jbc.271.14.8053. View

Yoon K, Hwangbo B, Kim I, Park S, Kim H, Kee H . Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis. 2006; 27(11):2217-22. DOI: 10.1093/carcin/bgl084. View

Feldman M, Apsel B, Uotila A, Loewith R, Knight Z, Ruggero D . Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7(2):e38. PMC: 2637922. DOI: 10.1371/journal.pbio.1000038. View

Hay N, Sonenberg N . Upstream and downstream of mTOR. Genes Dev. 2004; 18(16):1926-45. DOI: 10.1101/gad.1212704. View

Luyimbazi D, Akcakanat A, McAuliffe P, Zhang L, Singh G, Gonzalez-Angulo A . Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010; 9(10):2770-84. PMC: 2965451. DOI: 10.1158/1535-7163.MCT-09-0980. View

Brown M, Goldstein J . The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997; 89(3):331-40. DOI: 10.1016/s0092-8674(00)80213-5. View

Garcia-Martinez J, Alessi D . mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 2008; 416(3):375-85. DOI: 10.1042/BJ20081668. View

Han S, Jeon J, Ju H, Jung U, Kim K, Yoo H . VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene. 2003; 22(26):4035-46. DOI: 10.1038/sj.onc.1206610. View

10.

Sharpe L, Brown A . Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun. 2008; 373(4):670-4. DOI: 10.1016/j.bbrc.2008.06.108. View

11.

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung S . SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006; 127(1):125-37. DOI: 10.1016/j.cell.2006.08.033. View

12.

Lewis C, Griffiths B, Santos C, Pende M, Schulze A . Genetic ablation of S6-kinase does not prevent processing of SREBP1. Adv Enzyme Regul. 2010; 51(1):280-90. DOI: 10.1016/j.advenzreg.2010.09.001. View

13.

Hui S, Andres A, Miller A, Spann N, Potter D, Post N . Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A. 2008; 105(10):3921-6. PMC: 2268825. DOI: 10.1073/pnas.0800293105. View

14.

Ma K, Varghese Z, Ku Y, Powis S, Chen Y, Moorhead J . Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2010; 298(6):H1646-51. DOI: 10.1152/ajpheart.00492.2009. View

15.

Yu Y, Yoon S, Poulogiannis G, Yang Q, Ma X, Villen J . Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011; 332(6035):1322-6. PMC: 3195509. DOI: 10.1126/science.1199484. View

16.

Hsu P, Kang S, Rameseder J, Zhang Y, Ottina K, Lim D . The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332(6035):1317-22. PMC: 3177140. DOI: 10.1126/science.1199498. View

17.

Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H . Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem. 1999; 274(31):21645-50. DOI: 10.1074/jbc.274.31.21645. View

18.

Peng T, Golub T, Sabatini D . The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol. 2002; 22(15):5575-84. PMC: 133939. DOI: 10.1128/MCB.22.15.5575-5584.2002. View

19.

Apsel B, Blair J, Gonzalez B, Nazif T, Feldman M, Aizenstein B . Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008; 4(11):691-9. PMC: 2880455. DOI: 10.1038/nchembio.117. View

20.

Schmelzle T, Hall M . TOR, a central controller of cell growth. Cell. 2000; 103(2):253-62. DOI: 10.1016/s0092-8674(00)00117-3. View